InMed Pharmaceuticals (INM) Gains from Investment Securities (2021 - 2025)
Historic Gains from Investment Securities for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $196561.0.
- InMed Pharmaceuticals' Gains from Investment Securities rose 21492.09% to $196561.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $196561.0, marking a year-over-year increase of 21492.09%. This contributed to the annual value of $61410.0 for FY2025, which is 8210.66% up from last year.
- According to the latest figures from Q4 2025, InMed Pharmaceuticals' Gains from Investment Securities is $196561.0, which was up 21492.09% from $60356.0 recorded in Q3 2025.
- In the past 5 years, InMed Pharmaceuticals' Gains from Investment Securities ranged from a high of $678475.0 in Q1 2024 and a low of -$12307.0 during Q4 2022
- In the last 5 years, InMed Pharmaceuticals' Gains from Investment Securities had a median value of $62416.0 in 2024 and averaged $156664.5.
- As far as peak fluctuations go, InMed Pharmaceuticals' Gains from Investment Securities soared by 523272.93% in 2023, and later tumbled by 9088.19% in 2025.
- InMed Pharmaceuticals' Gains from Investment Securities (Quarter) stood at -$6030.0 in 2021, then crashed by 104.1% to -$12307.0 in 2022, then surged by 5232.73% to $631685.0 in 2023, then crashed by 90.12% to $62416.0 in 2024, then skyrocketed by 214.92% to $196561.0 in 2025.
- Its last three reported values are $196561.0 in Q4 2025, $60356.0 for Q3 2025, and $61864.0 during Q1 2025.